The making of a killer (T cell)

Por Overwijk, Willem W.
Publicado no Oncotarget (2017)

Functions of γC cytokines in immune homeostasis: current and potential clinical applications

Por Overwijk, Willem W., Schluns, Kimberly S.
Publicado em 2009

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard

Por Hailemichael, Yared, Overwijk, Willem W
Publicado em 2013

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination

Por Hailemichael, Yared, Overwijk, Willem W.
Publicado em 2014

Adjuvants for peptide-based cancer vaccines

Por Khong, Hiep, Overwijk, Willem W.
Publicado no J Immunother Cancer (2016)

Creating Therapeutic Cancer Vaccines: Notes from the Battlefield

Por Overwijk, Willem W., Restifo, Nicholas P.
Publicado em 2001

Autoimmunity and the Immunotherapy of Cancer: Targeting the “Self” to Destroy the “Other”

Por Overwijk, Willem W., Restifo, Nicholas P.
Publicado em 2000

B16 as a Mouse Model for Human Melanoma

Por Overwijk, Willem W., Restifo, Nicholas P.
Publicado em 2001

MOUSE MODEL FOR PRE-CLINICAL STUDY OF HUMAN CANCER IMMUNOTHERAPY

Por Ya, Zhiya, Hailemichael, Yared, Overwijk, Willem, Restifo, Nicholas
Publicado no Curr Protoc Immunol (2015)

The Future of Interleukin-2: Enhancing Therapeutic Anticancer Vaccines

Por Overwijk, Willem W., Theoret, Marc R., Restifo, Nicholas P.
Publicado em 2000

Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types

Por Frasca, Loredana, Stonier, Spencer W., Overwijk, Willem W., Schluns, Kimberly S.
Publicado em 2010

Cutting Edge: CD4(+) T Cell Control of CD8(+) T Cell Reactivity to a Model Tumor Antigen

Por Surman, Deborah R., Dudley, Mark E., Overwijk, Willem W., Restifo, Nicholas P.
Publicado em 2000

Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade

Por Singh, Manisha, Dai, Zhimin, Khong, Hiep, Vianden, Christina, Cantwell, Mark, Overwijk, Willem
Publicado no J Immunother Cancer (2015)

L-tyrosine is a promising cancer vaccine adjuvant

Por Khong, Hiep, Sharma, Meenu, Dai, Zhimin, Singh, Manisha, Hailemichael, Yared, Overwijk, Willem
Publicado no J Immunother Cancer (2015)

Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy

Por Hailemichael, Yared, Fu, Tihui, Khong, Hiep, Dai, Zhimin, Sharma, Padmanee, Overwijk, Willem W
Publicado no J Immunother Cancer (2014)

Soluble Interleukin-15 Complexes Are Generated In Vivo by Type I Interferon Dependent and Independent Pathways

Por Anthony, Scott M., Howard, Megan E., Hailemichael, Yared, Overwijk, Willem W., Schluns, Kimberly S.
Publicado no PLoS One (2015)

IL-2 analogues: novel agents circumventing the expansion of T regulatory cells while promoting NK cell activation during IL-2 therapy

Por Sim, Geok Choo, Grimm, Elizabeth, Dai, ZhiMin, Overwijk, Willem, Hwu, Patrick, Radvanyi, Laszlo
Publicado em 2013

Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors

Por Overwijk, Willem W, Wang, Ena, Marincola, Francesco M, Rammensee, Hans-Georg, Restifo, Nicholas P
Publicado em 2013

Characterization of the Inflammatory Microenvironment and Identification of Potential Therapeutic Targets in Wilms Tumors()()

Por Maturu, Paramahamsa, Overwijk, Willem W., Hicks, John, Ekmekcioglu, Suhendan, Grimm, Elizabeth A., Huff, Vicki
Publicado em 2014

Induction of systemic anti-melanoma immunity through intratumoral TLR-7/8 activation

Por Singh, Manisha, Khong, Hiep, Dai, Zhimin, Vasilakos, John P, Hwu, Patrick, Overwijk, Willem W
Publicado no J Immunother Cancer (2014)